(Q28238012)

Metallopanstimulin as a marker for head and neck cancer

21 January 2018

1 reference

7 January 2021

The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck

1 reference

7 January 2021

Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.

1 reference

7 January 2021

Matrix metalloproteinases

1 reference

7 January 2021

Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry

1 reference

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

7 January 2021

How matrix metalloproteinases regulate cell behavior

1 reference

7 January 2021

Cervical node metastasis from epidermoid carcinoma of the oral cavity and oropharynx. A critical assessment of current staging

1 reference

7 January 2021

Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases

1 reference

7 January 2021

Lymph node prognostic factors in head and neck squamous cell carcinomas

1 reference

7 January 2021

Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor

1 reference

7 January 2021

Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma

1 reference

7 January 2021

Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells

1 reference

7 January 2021

Enhanced Production of Matrix Metalloproteinase-2 in Human Head and Neck Carcinomas is Correlated with Lymph Node Metastasis

1 reference

7 January 2021

Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer

1 reference

7 January 2021

Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential

1 reference

7 January 2021

Activation of matrix metalloproteinase-2 in head and neck squamous cell carcinoma: studies of clinical samples and in vitro cell lines co-cultured with fibroblasts.

1 reference

7 January 2021

Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinicopathologic study

1 reference

7 January 2021

Expression of matrix metalloproteinase-3 in stage I and II squamous cell carcinoma of the oral cavity

1 reference

7 January 2021

Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma

1 reference

7 January 2021

Role of membrane type 1-matrix metalloproteinase and gelatinase A in head and neck squamous cell carcinoma invasion in vitro

1 reference

7 January 2021

Expression of proteolytic enzymes in head and neck cancer-associated fibroblasts

1 reference

7 January 2021

Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion

1 reference

7 January 2021

Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma

1 reference

7 January 2021

Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx

1 reference

7 January 2021

Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis

1 reference

7 January 2021

Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis

1 reference

7 January 2021

Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker

1 reference

7 January 2021

Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein

1 reference

7 January 2021

Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma

1 reference

7 January 2021

Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma.

1 reference

7 January 2021

Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma

1 reference

7 January 2021

Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization

1 reference

7 January 2021

Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours

1 reference

7 January 2021

Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma

1 reference

7 January 2021

Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course

1 reference

7 January 2021

A new assay to screen for head and neck squamous cell carcinoma using the tumor marker metallopanstimulin

1 reference

7 January 2021

Identification of patients with head and neck cancer using serum protein profiles

1 reference

7 January 2021

Serum protein profiles to identify head and neck cancer

1 reference

7 January 2021

The Measurement of Observer Agreement for Categorical Data

1 reference

7 January 2021

Surveillance for recurrent head and neck cancer using positron emission tomography

1 reference

7 January 2021

Hexokinase-II expression in untreated oral squamous cell carcinoma: comparison with FDG PET imaging

1 reference

7 January 2021

Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study

1 reference

7 January 2021

Matrix metalloproteinase inhibitors as anticancer therapeutics.

1 reference

7 January 2021

Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases

1 reference

7 January 2021

COPD: current therapeutic interventions and future approaches

1 reference

7 January 2021

A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops

1 reference

7 January 2021

Inhibition of cervical lymph node metastasis by marimastat (BB-2516) in an orthotopic oral squamous cell carcinoma implantation model

1 reference

7 January 2021

Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer

1 reference

7 January 2021

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial

1 reference

7 January 2021

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

1 reference

7 January 2021

Exploiting molecular targets in pancreatic cancer

1 reference

7 January 2021

Matrix metalloproteinase inhibitors

1 reference

7 January 2021

Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck

1 reference

7 January 2021

Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients

1 reference

7 January 2021

Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis

1 reference

7 January 2021

Fusaric acid: a novel agent and mechanism to treat HNSCC.

1 reference

7 January 2021

Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin

1 reference

7 January 2021

The effect of single agent oral fusaric acid (FA) on the growth of subcutaneously xenografted SCC-1 cells in a nude mouse model

1 reference

7 January 2021